NCT01510990View on ClinicalTrials.gov

First Line Gefitinib by FDG-PET Metabolic Response

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

November 30, 2015

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Gefitinib

gefitinib 250mg/day daily

Trial Locations (1)

138-736

RECRUITING

Asan Medical Center, Seoul

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
lead

Asan Medical Center

OTHER

collaborator

AstraZeneca

INDUSTRY